Assessment of Blood and Follicular Fluid Immune Cell Constitution in Patients Undergoing in Vitro Fertilization
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01083745
Verified March 2010 by Hillel Yaffe Medical Center. Recruitment status was: Not yet recruiting
The etiology of infertility in the majority of patients with poor response to ovarian stimulation remains unknown. This study will investigate the role of immune cells (T cells, B cells, dendritic cells and NK cells), that constitute the immune system which normally fights infection and cancer. We, the investigators, have found that specialized NK cells that help with new blood vessel formation, are found in the fluid surrounding the egg during IVF, only in patients with good response to ovarian stimulation. We now wish to expand our studies and correlate our findings to ovarian blood flow , as measured by 3D ultrasound and to the presence of other cells in the immune system.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
27 Years to 43 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
IVF clinic patients in tertiary care center
Age 27-43 years
Diagnosis of infertility due to endometriosis, severe male factor, tubal occlusion.
Patient undergoing IVF
Body mass index (BMI) > 38 kg/m2
Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
Any current use of systemic steroid medication or any infertility treatment within 3 months of study enrollment.
Any contraindication to being pregnant and carrying a pregnancy to term.
Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.
History (within past 12 months) or current abuse of alcohol or drugs.
Administration of any investigational drugs within three months prior to study enrollment.
Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction
Unexplained gynecological bleeding.
Ejaculated sperm is not sufficient for ICSI
Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
Abnormal COH screening blood done for both partners, including: prolactin, thyroid stimulating hormone, HIV serology, Hepatitis B and C serology, Rubella, group and screen and syphilis serology prior to participation in study.
Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.